Life Science REIT (LABS) ORD GBP0.01

Sell:37.50pBuy:37.90p0.30p (0.80%)

FTSE All Share:0.18%
Market closed |
Prices delayed by at least 15 minutes
Sell:37.50p
Buy:37.90p
Change:0.30p (0.80%)
Market closed |
Prices delayed by at least 15 minutes
Sell:37.50p
Buy:37.90p
Change:0.30p (0.80%)
Market closed |
Prices delayed by at least 15 minutes

Trust Information

About this company

Life Science REIT plc is a closed-ended real estate investment trust. The Company’s investment objective is to provide shareholders with an attractive level of total return. It seeks to invests in a diversified portfolio of properties across the United Kingdom, which are typically leased or intended to be leased to tenants operating in, or providing a benefit to, the life science sector. It acquires or develops properties, such as wet and dry laboratories, offices, incubators and co-working space, manufacturing and testing facilities and data centers. The Company retains flexibility to acquire individual buildings, a group of buildings across a single science park or the entirety of a science park. It also includes purchasing or developing buildings that are leased or intended to be leased to occupiers providing ancillary services to employees of companies operating in, or providing a benefit to, the life science sector. Its investment adviser is Ironstone Asset Management Limited.

Objective

The Company will seek to achieve its investment objective by investing in a diversified portfolio of properties across the UK which are typically leased or intended to be leased to tenants operating in, or providing a benefit to, the life science sector. Life science is the branch of sciences concerned with the study of living organisms. This encompasses the study of the breadth of life processes, and the structure and behaviour of living things. Companies operating in the life science sector include, but are not limited to, those involved in the innovation, development and/or production of assets directly or indirectly for human health purposes.

Costs

  • Ongoing charge1.10%
  • Annual management charge -
  • Performance feeNo

Fee structure

The advisory fee, payable quarterly, is based on the lower of NAV or average market capitalisation at 1% up to GBP 500m, 0.9% up to GBP 1bn, and 0.75% above GBP 1bn. The Investment Advisers four-year term is terminable on 24 months notice from the fourth anniversary of Admission.

Value Assessment

  • Value Assessment review date30 June 2024
  • Value Assessment next review date30 June 2025
  • Is Assessment of Value required under COLL?Yes
  • Outcome of COLL Assessment of ValueCharges are justified based on the results of the assessment, or based on assessment against initial product design if an assessment not yet due
  • Outcome of PRIN Value Assessment or reviewn/a
  • Other review related to value and or charges -
  • Further information-
Click to see more

Key facts

  • Currency
    GBX
  • Benchmark
    No benchmark
  • Shares in issue
    350.00m
  • Gross gearing
    46.00%
  • EPIC
    LABS
  • ISIN
    GB00BP5X4Q29
  • Domicile
    United Kingdom
  • Exchange
    London Stock Exchange (LON)
  • Index
    FTSE All Share Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview of the company, currency, shares in issue, EPIC, location, exchange, index, website, Data sourced by LSEG. Objective, Costs, Fee Structure, Key facts including Benchmark, Gross gearing are provided by MorningStar.